Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials.
Mietlowski
William
W
Wang
Jinping
J
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D002986:Clinical Trials as Topic / Q000379:methods*; D018450:Disease Progression; D018572:Disease-Free Survival; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D008954:Models, Biological; D012107:Research Design
D020533:Angiogenesis Inhibitors